Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Deferred Income Tax
â‚ą2m
CAGR 3-Years
-83%
CAGR 5-Years
-56%
CAGR 10-Years
-42%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Deferred Income Tax
â‚ą841m
CAGR 3-Years
43%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Deferred Income Tax
â‚ą1.9B
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
-5%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Deferred Income Tax
â‚ą1.9B
CAGR 3-Years
59%
CAGR 5-Years
28%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Deferred Income Tax
â‚ą7.9B
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
20%
M
Mankind Pharma Ltd
NSE:MANKIND
Deferred Income Tax
â‚ą890.7m
CAGR 3-Years
90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
243B INR
Industry
Pharmaceuticals

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Deferred Income Tax?
Deferred Income Tax
2m INR

Based on the financial report for Jun 30, 2024, Natco Pharma Ltd's Deferred Income Tax amounts to 2m INR.

What is Natco Pharma Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
-42%

Over the last year, the Deferred Income Tax growth was -98%. The average annual Deferred Income Tax growth rates for Natco Pharma Ltd have been -83% over the past three years , -56% over the past five years , and -42% over the past ten years .

Back to Top